Study on Nipocalimab for Adults with Active Inflammatory Muscle Diseases
- Substances:Nipocalimab
Germany- Participants:18–64 years · 65+ years
- Substances:Nipocalimab
- Sponsor:Janssen Cilag International
Rare diseases
Investigational molecules
Locations
Back to Germany1 191 clinical trials in Munich, Germany across 8 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)
GermanyStudy of Pembrolizumab and Enfortumab Vedotin with Surgery vs. Surgery Alone for Patients with Muscle-Invasive Bladder Cancer Who Cannot or Choose Not to Use Cisplatin
GermanyStudy on the Effectiveness and Safety of Tisagenlecleucel for Adults with Hard-to-Treat or Returning Follicular Lymphoma
GermanyStudy of MK-7684A and Pembrolizumab for Patients with Advanced Solid Tumors
GermanyStudy of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and Pembrolizumab for Patients with Advanced Head and Neck Cancer
GermanyStudy on Bepranemab for Patients with Early Alzheimer's Disease
GermanyStudy of Epcoritamab for Patients with Relapsed, Progressive, or Refractory B-Cell Lymphoma
GermanyStudy of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery
GermanyStudy on the Effectiveness and Safety of AZD4604 for Adults with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
GermanyStudy on DFV890 and MAS825 for Reducing Inflammation in Adults with Coronary Heart Disease and Clonal Hematopoiesis
GermanyStudy on the Effectiveness and Safety of Remibrutinib Compared to Placebo and Omalizumab in Adults with Chronic Spontaneous Urticaria Uncontrolled by Antihistamines
GermanyStudy of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer
GermanyThe busiest research cities in the country
What the registry says about research in the country
In München, clinical trials in oncology and blood cancers focus on improving survival, controlling relapse, and refining treatment strategies for a wide range of cancers.
These studies are testing new combinations and comparative approaches to strengthen cancer control and better support patients with advanced or hard-to-treat disease.
Trials in cardiovascular medicine are examining ways to lower major events, improve post-procedure care, and optimize long-term protection in high-risk patients.
Much of this work aims to improve treatment effectiveness while reducing serious cardiovascular complications.
Respiratory research in this city is broad, with studies centered on chronic lung disease, inflammation, and treatment options for people with difficult-to-control symptoms.
These trials are mainly evaluating whether new therapies can improve breathing, symptom control, and long-term lung outcomes.
Neurological research spans emergency stroke care, chronic neurodegenerative disorders, and therapies aimed at preserving daily function and quality of life.
Research here is exploring better acute treatments, symptom relief, and disease-modifying approaches for progressive neurological conditions.
Several studies address immune-mediated diseases, including skin disorders and systemic inflammatory conditions, with the goal of improving symptom control and reducing flare burden.
These trials are assessing whether newer targeted treatments can provide better and more durable relief for inflammatory disease.
Research in metabolic disease focuses on diabetes control, obesity management, and reduction of long-term cardiometabolic risk.
The overall aim is to test therapies that may improve glucose control, support weight loss, and lower future complications.
Eye disease trials are looking at ways to protect vision and slow progression in conditions that can lead to irreversible damage.
These studies are designed to improve treatment options for patients facing progressive vision loss.
Clinical research in infectious disease includes both prevention and treatment, with attention to viral infection and serious respiratory illness.
These trials aim to strengthen prevention strategies and improve outcomes in infections that can place a heavy burden on patients and healthcare systems.
Studies in urology and kidney disease address both cancer and transplant-related care, along with advanced prostate cancer.
Research in this area is focused on improving treatment effectiveness, organ outcomes, and long-term patient safety.
Trials here cover musculoskeletal disease and persistent pain, seeking better ways to relieve symptoms that often limit mobility and daily activity.
The main goal is to evaluate therapies that may provide stronger and more lasting pain relief.
Several studies in München address rare diseases and childhood cancers, where new treatment approaches are especially important.
These trials are testing ways to improve outcomes for young patients with aggressive or recurrent disease.
Some studies bridge allergy, inflammation, and respiratory disease, reflecting the role of immune pathways in chronic symptoms.
These trials are evaluating targeted treatments that may better control inflammation and reduce flare-ups.
A portion of the trial portfolio does not fit neatly into one specialty, reflecting broad research across overlapping medical conditions and complex patient groups.
These studies often aim to improve overall treatment benefit, safety, and real-world applicability across different patient populations.
Tell us about your condition – we search every trial in Europe and connect you with the right site.